Inventiva (NASDAQ:IVA) Now Covered by Analysts at TD Cowen

TD Cowen began coverage on shares of Inventiva (NASDAQ:IVA) in a research report issued to clients and investors on Friday,Briefing.com Automated Import reports. The brokerage set a “buy” rating and a $10.00 price target on the stock. TD Cowen’s price target would suggest a potential upside of 266.97% from the stock’s current price.

Several other brokerages also recently weighed in on IVA. UBS Group initiated coverage on Inventiva in a research note on Tuesday, November 12th. They set a “neutral” rating and a $3.00 target price for the company. Stifel Nicolaus cut their price target on Inventiva from $20.00 to $17.00 and set a “buy” rating for the company in a report on Friday, November 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $13.00 price target on shares of Inventiva in a report on Thursday, January 30th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $12.60.

Inventiva Stock Performance

Shares of NASDAQ:IVA opened at $2.73 on Friday. The business has a 50 day moving average price of $2.32 and a 200 day moving average price of $2.36. Inventiva has a twelve month low of $1.53 and a twelve month high of $4.50.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.